業績方面，公司透過新聞稿（附件99.1）披露了該季度的運營及財務數據，但8-K正文未提供具體數字，需參考新聞稿原文。

crvo20260518_8k.htm

 

false
0001053691

0001053691

2026-05-18
2026-05-18

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

 

May 18, 2026

Date of Report (Date of earliest event reported)

 

 

CervoMed Inc.

(Exact name of registrant as specified in its charter)

 

 

 
 
 Delaware

 
 
 001-37942

 
 
 30-0645032

 
 

 
 
 (State or other jurisdiction

 of incorporation)

 
 
 (Commission

 File Number)

 
 
 (I.R.S. Employer

 Identification No.)

 
 

 
  
  
 

 
 
 20 Park Plaza, Suite 424

 Boston, Massachusetts

 
 
 02116

 
 

 
 
 (Address of principal executive offices)

 
 
 (Zip Code)

 
 

 

Registrant’s telephone number, including area code: (617) 744-4400

 

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 
 
 ☐

 
 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
 

 

 
 
 ☐

 
 
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
 

 

 
 
 ☐

 
 
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
 

 

 
 
 ☐

 
 
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

 
 
 Title of each class

 
  
 
 Trading

 Symbol(s)

 
  
 
 Name of each exchange

 on which registered

 
 

 
 
 Common Stock, $0.001 par value

 
  
 
 CRVO

 
  
 
 NASDAQ Capital Market

 
 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 
 
 Item 2.02

 
 
 Results of Operations and Financial Condition

 
 

 

On May 18, 2026, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the three months ended December 31, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

 
 
 Item 7.01

 
 
 Regulation FD Disclosure

 
 

 

Anticipated Cash Runway

 

As previously announced, as of March 31, 2026, we had approximately $12.9 million in cash, cash equivalents and marketable securities. Based on our current operating plan, we believe our cash, cash equivalents, and marketable securities on hand as of March 31, 2026, will enable the Company to fund its planned operating expenses and capital expenditure requirements into September 2026.

 

--

 

The information in or incorporated by reference into Items 2.02 and 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

 
 
 Item 9.01

 
 
 Financial Statements and Exhibits

 
 

 

 
 
 (d)

 
 
 Exhibits

 
 

 

 
 
 Exhibit No.

 
 
 Description

 
 

 
 
 99.1 

 
 
 Press Release, issued May 18, 2026

 
 

 
 
 104

 
 
 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 
 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
 
 Date: May 18, 2026

 
 
 CervoMed Inc.

 
  
 

 
  
  
  
  
 

 
  
 
 By:

 
 
 /s/ William Elder

 
  
 

 
  
 
 Name:

 
 
 William Elder

 
  
 

 
  
 
 Title:

 
 
 Chief Financial Officer & General Counsel